Compare LBRDK & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDK | COGT |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.5B |
| IPO Year | N/A | 2018 |
| Metric | LBRDK | COGT |
|---|---|---|
| Price | $44.09 | $39.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $30.17 |
| AVG Volume (30 Days) | 1.1M | ★ 2.4M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.38 | N/A |
| EPS | ★ 5.51 | N/A |
| Revenue | ★ $1,016,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.46 | N/A |
| P/E Ratio | $8.02 | ★ N/A |
| Revenue Growth | ★ 306.40 | N/A |
| 52 Week Low | $43.77 | $3.72 |
| 52 Week High | $104.00 | $43.73 |
| Indicator | LBRDK | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 31.41 | 60.74 |
| Support Level | $47.10 | $33.84 |
| Resistance Level | $49.62 | $36.88 |
| Average True Range (ATR) | 1.53 | 1.93 |
| MACD | -0.40 | 0.07 |
| Stochastic Oscillator | 4.63 | 75.53 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.